Targeted Therapy with Larotrectinib in NTRK Fusion Cancers: Results from the NCI-MATCH ECOG-ACRIN Trial
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 27, 2026. n Precision oncology has transformed cancer
Patient Resources
Resources
Guides on importing specialty medicines, prescription requirements and country rules — written for patients and carers arranging treatment across Southeast Asia and Oceania.
Guides — page 3
-
-
FDA Gives Full Approval to Encorafenib Combo for BRAF V600E Metastatic Colorectal Cancer
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 26, 2026. n The US FDA has granted
-
Oral SERDs Explained: The New Hormone Therapy Option After Endocrine Resistance in HR+ Breast Cancer
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 25, 2026. n Hormone receptor-positive, HER2-negative breast cancer
-
New First-Line Option: FDA Approves Acalabrutinib Combo for CLL/SLL
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 24, 2026. n A new frontline treatment option
-
Venetoclax–Rituximab Retreatment in CLL: What a 100% Response Rate Means for Patients
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 23, 2026. n Chronic lymphocytic leukemia (CLL) treatment
-
Fixed-Duration Venetoclax vs Continuous Ibrutinib in Untreated CLL: What the CLL17 Trial Means for Patients
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 21, 2026. n Chronic lymphocytic leukemia (CLL) is
-
Does Ribociclib Still Help After 3 Years? The NATALEE Trial’s 4-Year Follow-Up Answers
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 21, 2026. n For patients with hormone receptor–positive,
-
New CDK4/6 Strategies in HR+/HER2– Breast Cancer: Imlunestrant ± Abemaciclib and the Avutometinib Triplet
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 20, 2026. n Hormone receptor–positive, HER2-negative (HR+/HER2–) metastatic
-
CDK4/6 Inhibitors in Prostate Cancer: What CYCLONE 2 Tells Us About Abemaciclib + Abiraterone
Metastatic castration-resistant prostate cancer (mCRPC) remains one of the most challenging stages of prostate cancer to treat. Although several therapies
-
Colonoscopy: A Comprehensive Guide to Procedure, Preparation, and Prevention
Colonoscopy remains one of the most effective diagnostic and preventive procedures in modern medicine, playing a critical role in the
Still have a question?
We reply to every enquiry within one working day.